• 1
    Centers for Disease Control and Prevention (CDC). Racial/ethnic disparities in prevalence, treatment, and control of hypertension—United States, 1999–2002. MMWR Morb Mortal Wkly Rep. 2005;54:79.
  • 2
    Ferdinand KC, Saunders E. Hypertension-related morbidity and mortality in African Americans-why we need to do better. J Clin Hypertens (Greenwich). 2006;8(suppl 1):2130.
  • 3
    Sowers JR, Ferdinand KC, Bakris GL, et al. Hypertension-related disease in African Americans: factors underlying disparities in illness and its outcome. Postgrad Med. 2002;112:2448.
  • 4
    Stein CM, Lang CC, Singh I, et al. Increased vascular adrenergic vasoconstriction and decreased vasodilation in blacks: additive mechanisms leading to enhanced vascular reactivity. Hypertension. 2000;36:945951.
  • 5
    Jones DS, Andrawis NS, Abernethy DR. Impaired endothelial dependent forearm vascular relaxation in black Americans. Clin Pharmacol Ther. 1999;65:408412.
  • 6
    Cardillo C, Kilcoyne CM, Cannon RO III, et al. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation. 1999;99:9095.
  • 7
    Cardillo C, Kilcoyne CM, Cannon RO III, et al. Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension. 1998;31:12351239.
  • 8
    Lang CC, Stein CM, He HB, et al. Blunted blood pressure response to central sympathoinhibition in normotensive blacks: increased importance of nonsympathetic factors in blood pressure maintenance in blacks. Hypertension. 1997;30:157162.
  • 9
    Holland OB, Chud JM, Braunstein H. Urinary kallikrein excretion in essential and mineralocorticoid hypertension. J Clin Invest. 1980;65:347356.
  • 10
    Preston RA, Materson BJ, Reda DJ, et al. for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA. 1998;280:11681172.
  • 11
    Wu J, Kraja AT, Oberman A, et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens. 2005;18:935942.
  • 12
    Cushman WC, Reda DJ, Perry HM Jr, et al, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch Intern Med. 2000;160:825831.
  • 13
    Prichard BN, Cruickshank JM, Graham BR. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press. 2001;10:366386.
  • 14
    Weber MA. The role of the new β-blockers in treating cardiovascular disease. Am J Hypertens. 2005;18(suppl 1):169S176S.
  • 15
    Van de Water A, Janssens W, Van Neuten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective β1-adrenergic antagonist. J Cardiovasc Pharmacol. 1988;11:552563.
  • 16
    Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol. 1994;38:199204.
  • 17
    Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:10671071.
  • 18
    Dawes M, Brett SE, Chowienczyk PJ, et al. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol. 1999;48:460463.
  • 19
    Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104:511514.
  • 20
    Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol. 2001;38(suppl 3):S13S16.
  • 21
    Bristow MR, Nelson P, Minobe W, Johnson C. Characterization of β1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium. Am J Hypertens. 2005;18(pt 2):51A52A. Abstract P-121.
  • 22
    Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third-generation β-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003;107:27472752.
  • 23
    Mason RP, Kalinowski L, Jacob RF, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:37953801.
  • 24
    Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344348.
  • 25
    McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs. 1999;57:633651.
  • 26
    Ambrosioni E, Borghi C. Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective β-blockers in the treatment of hypertension: a meta-analysis. High Blood Press Cardiovasc Prev. 2005;12:2735.
  • 27
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199206.
  • 28
    The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 29
    Rehman SU, Hutchison FN, Hendrix K, et al. Ethnic differences in blood pressure control among men at veterans affairs clinics and other health care sites. Arch Intern Med. 2005;165:10411047.
  • 30
    Sheats N, Lin Y, Zhao W, et al. Prevalence, treatment, and control of hypertension among African Americans and Caucasians at primary care sites for medically under-served patients. Ethn Dis. 2005;15:2532.
  • 31
    Prisant LM, Mensah GA. Use of β-adrenergic receptor blockers in blacks. J Clin Pharmacol. 1996;36:867873.
  • 32
    Everly MJ, Heaton PC, Cluxton RJ Jr. β-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother. 2004;38:286293.
  • 33
    Mokwe E, Ohmit SE, Nasser SA, et al. Determinants of blood pressure response to quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation Trial. Hypertension. 2004;43:12021207.
  • 34
    Van Nueten L, Dupont AG, Vertommen C, et al. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens. 1997;11:139144.
  • 35
    Toda N. Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther. 2003;100:215234.
  • 36
    Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9(4):269277.
  • 37
    Galderisi M, Cicala S, D'Errico A, et al. Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease. J Hypertens. 2004;22:22012208.
  • 38
    Gullu H, Erdogan D, Caliskan M, et al. Different effects of atenolol and nebivolol on coronary flow reserve. Heart. 2006;92:16901691.
  • 39
    Charles H, Good CB, Hanusa BH, et al. Racial differences in adherence to cardiac medications. J Natl Med Assoc. 2003;95:1727.
  • 40
    Monane M, Bohn RL, Gurwitz JH, et al. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health. 1996;86:18051808.
  • 41
    Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19:11901196.
  • 42
    Laragh JH, Letcher RL, Pickering TG. Renin profiling for diagnosis and treatment of hypertension. JAMA. 1979;241:151156.
  • 43
    Buhler FR, Burkart F, Lutold BE, et al. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol. 1975;36:653669.
  • 44
    Chan TY, Woo KS, Nicholls MG. The application of nebivolol in essential hypertension: a double-blind, randomized, placebo-controlled study. Int J Cardiol. 1992;35:387395.